What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Pembrolizumab shows a moderate benefit over current care, with statistically significant improvements in recurrence-free survival (HR 0.59) and distant metastases-free survival (HR 0.60) compared to placebo. However, overall survival data remains immature, limiting the strength of the evidence.
Does the economic case hold at the expected price? — Cost effectiveness
The most conservative ICER estimate is £26,493 per QALY gained, which is within acceptable thresholds for Healthcare resources. The committee concluded that pembrolizumab is a cost-effective use of resources, especially considering its administration schedule.
Is there quality-of-life evidence payers weigh? — Quality of life
While specific HRQoL data is not detailed, the committee noted that recurrence-free survival is a significant outcome for patients, indicating a moderate improvement in quality of life associated with the treatment.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Pembrolizumab is generally well tolerated, with 80% of patients experiencing no toxicity. However, there are notable risks of high toxicity (5-10%), which require careful monitoring, but overall, the safety profile is favorable compared to existing therapies.
Was the drug compared against what payers expect? — Comparator Selection
The treatment was compared against placebo in a well-designed RCT (KEYNOTE-054), which is appropriate given the context of adjuvant therapy for melanoma. The committee acknowledged the relevance of the comparator.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population is moderately representative of the intended patient population, with a median age of 53.9 years and a significant proportion of patients with BRAF mutations. However, some subgroup data is limited.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Pembrolizumab can be integrated into existing care pathways with minor adjustments, as it is administered every 6 weeks, which is preferable for patients compared to other treatments like nivolumab.
Are the wider system costs understood? — Resource Use and Cost Implications
The treatment is expected to have a manageable budget impact, especially considering the potential reduction in administration costs due to less frequent dosing compared to alternatives.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence is based on a robust RCT design (KEYNOTE-054) with a significant sample size (1,019 participants). However, the immaturity of overall survival data introduces some methodological concerns.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There is high uncertainty regarding overall survival estimates due to the ongoing nature of the trial and the reliance on surrogate endpoints. This uncertainty may affect decision-making and restrict use.
